Loading issue research
Support therapeutic somatic genome medicine with safety registries, access, privacy, manufacturing capacity, and a hard clinical boundary around reproductive germline editing.
Verification Status
AI-researched, unverifiedLast Reviewed
Jul 6, 2026
Cited Sources
6
What is failing, what we would change, and the conclusion we are willing to defend.
Genome medicine is no longer theoretical. FDA approved Casgevy and Lyfgenia for sickle cell disease in 2023, making Casgevy the first FDA-approved therapy using CRISPR/Cas9 genome editing. In July 2026, FDA expanded Casgevy to patients as young as age 2 with sickle cell disease or transfusion-dependent beta thalassemia. FDA's approved cell and gene therapy list now includes a growing set of products, while NIH's Somatic Cell Genome Editing program is building tools and delivery systems for non-reproductive cells.
The Innovation Party should take a positive, disciplined position: accelerate therapeutic somatic editing, cell therapy, and programmable treatment for serious disease, but do not permit clinical reproductive germline editing until safety, consent, and governance standards exist that the country does not currently have.
Fund somatic genome-editing delivery systems, assays, manufacturing methods, and standards through NIH, FDA, ARPA-H, NIST, and public-private consortia.
Strengthen FDA review capacity for cell and gene therapies so flexible development pathways do not become weak evidence pathways.
Require long-term safety and efficacy registries for approved genome-editing and cell therapies, with privacy, consent, adverse-event reporting, and equity monitoring.
Build access and payment models for curative therapies so public investment does not create treatments only wealthy patients or large health systems can reach.
Enforce against unapproved stem-cell and gene-editing clinics that sell speculative cures.
Maintain a clear boundary: clinical reproductive germline editing stays outside approved care while governed basic research and ethical debate continue under existing restrictions.
The party should be for cures and against biological recklessness. A serious innovation platform can say both without contradiction.
Turn frustration into useful pressure.
If this position misses evidence or a lived consequence, challenge it. If it holds up, help test it locally and connect it to the issues around it.